Loading…
ProQR Therapeutics N.V.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in PRQR.
▼ -78.6% over 5Y.
today you would have $197.13▼ -80.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $2.02 | $2.65 | $1.98 | $3.70 | |
| P/S | 19.7x | 13.4x | 14.7x | 24.7x | 83.2x |
| P/B | 4.1x | 4.3x | 3.1x | 3.9x | 4.5x |
| EPS | -$0.40 | -$0.32 | -$0.35 | -$0.90 | |
| Profit margin | -348.44% | -265.21% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| EYPTEyePoint, Inc. | $3.72 | — | 9.4x | — | -148.70% | $320.71M |
| RCELAVITA Medical, Inc. | $10.35 | — | — | — | — | $320.09M |
| VCREVicore Pharma Holding AB | $11.31 | — | — | — | -56.99% | $318.41M |
| IFRXInflaRx N.V. | $2.23 |
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Company description provided by Yahoo Finance.
| -146.86% |
| -431.67% |
| -1792.54% |
| ROE | -76.69% | -85.44% | -31.35% | -67.94% | -96.06% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 1.9x |
| — |
| -38.52% |
| $328.63M |
| SMTISanara MedTech Inc. | $34.57 | — | 45.1x | — | -1.32% | $317.63M |
| ABEOAbeona Therapeutics Inc | $5.53 | — | 2.5x | — | -43.13% | $316.23M |